Company Overview and News
Bill Miller and others have recently argued that the real mistake value investors are making today is not including the most popular stocks in the market in their portfolios. I would argue just the opposite: that the real mistake value investors are making today, at least the ones really looking value, is trying to be contrarian by following the consensus.
begin 644 filename1.pdf M)5!$1BTQ+C4-"B6UM;6U#0HQ(# @;V)J#0H\/"]4>7!E+T-A=&%L;V7!E+U!A9V5S+T-O=6YT(#(O2VED7!E+U!A9V4O4&%R96YT(#(@,"!2+U)E M'1'4W1A=&4\/"]'4S<@-R P(%(O M1U,X(#@@,"!2/CXO6$]B:F5C=#P\+TEM86=E.2 Y(# @4CX^+U!R;V-3971; M+U!$1B]497AT+TEM86=E0B]);6%G94,O26UA9V5)72 ^/B]-961I84)O>%[email protected] M," P(#8Q,B W.3)=("]#;VYT96YT
Rite Aid Corporation delivered mixed results for first-quarter fiscal 2019, wherein the bottom line lagged estimates while sales topped. Further, the bottom line was flat with the prior-year quarter and the top line declined marginally. It was also the second straight quarter of improved adjusted EBITDA for the Retail Pharmacy segment, which led to increased adjusted EBITDA for the company. Other key highlights of the reported quarter included the transfer of 281 stores to Walgreens , which completed the company’s store transfer process.
HLF RAD BKE
Herbalife Nutrition Ltd. (HLF - Free Report) has delivered a marvellous bull-run in the past six months. This nutrition solutions provider has seen its shares rally 53.2%, against the industry’s decline of nearly 3%. Let’s delve into the factors that are most likely to continue driving this Zacks Rank #2 (Buy) company.
HLF BURL URBN
Walgreens Boots Alliance, Inc. (WBA - Free Report) was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $62.39 to $65.80 in the past one-month time frame. The move came after the company is set to join the Dow Jones Industrial Average by replacing General Electric Co.
HLF GEC GE HII WBA GNE
Herbalife is boosting the North America sales leader numbers with a newly introduced "re-qualification equalization factor".
Chicago, IL – June 18, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Urban Outfitters, Inc. (URBN - Free Report) , Insight Enterprises, Inc. (NSIT - Free Report) , Tilly's, Inc. (TLYS - Free Report) , Herbalife Nutrition Ltd.
SAPGF TLYS ENSG TSCDY GIII TESO HLF SAP BSX IFNNY KMG IFNNF URBN TSCDF NSIT TSCO
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
NPSNY SYY RUTH LX MS DECK SRRK EQIX JACK MDT TACOW KNSA VZ ZOES FB CLPS QNST MCRI KR SMTC CCL RYDAF EVOP INTC DRRX ICLK MUSA ITUB BB UNFI RHT PTIE HLF JPM MU FNKO HBNC SBUX LOCO PLAY XOM TWX MS.PRE MS.PRF MS.PRG RDSB TOT RDSA MS.PRA SHAK HMNY SAFM BKS AAN OSTK GSKY INCY CTLR CCL BP MS.PRI GOOGL MS.PRK FLL RYDBF MKSI FITB CLR BB PPC BC NDLS DOGZ FND DRI SGBXQ FINL WGO COP XHR DAL ORCL DIS JASO F RDS.B RDS.A TACO DISH TMSR SPTN FDX VLO GOLF CHUY SNY CHEF W ITRM SGBX CVX SNE
2018-07-17 - Asif
History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...
2018-07-17 - Asif
Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...
2018-07-16 - Asif
General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...
as of ET